Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) EBT (2019 - 2025)

Legend Biotech filings provide 7 years of EBT readings, the most recent being -$19.7 million for Q4 2025.

  • On a quarterly basis, EBT fell 148.64% to -$19.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$84.4 million, a 46.6% increase, with the full-year FY2025 number at -$282.6 million, down 78.75% from a year prior.
  • EBT hit -$19.7 million in Q4 2025 for Legend Biotech, up from -$39.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $112.0 million in Q1 2023 to a low of -$198.8 million in Q2 2023.
  • Median EBT over the past 5 years was -$61.1 million (2023), compared with a mean of -$57.1 million.
  • Biggest five-year swings in EBT: plummeted 33858.75% in 2022 and later skyrocketed 27686.3% in 2024.
  • Legend Biotech's EBT stood at -$88.3 million in 2021, then tumbled by 53.65% to -$135.7 million in 2022, then skyrocketed by 99.89% to -$146812.0 in 2023, then skyrocketed by 27686.3% to $40.5 million in 2024, then tumbled by 148.64% to -$19.7 million in 2025.
  • The last three reported values for EBT were -$19.7 million (Q4 2025), -$39.1 million (Q3 2025), and -$124.8 million (Q2 2025) per Business Quant data.